Peptides spanning the fusion region of Abl/Bcr are immunogenic and sensitize CD8(+) T lymphocytes to recognize native chronic myelogenous leukemia.
Wagner
W M
WM
Ouyang
Q
Q
Pawelec
G
G
D016827:CD8 Antigens; D003602:Cytotoxicity, Immunologic / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology*; D016044:Fusion Proteins, bcr-abl / Q000276:immunology*; D015234:HLA-A Antigens / Q000276:immunology; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology* / Q000378:metabolism / Q000628:therapy; D008213:Lymphocyte Activation; D008285:Major Histocompatibility Complex / Q000276:immunology*; D010446:Peptide Fragments / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*; D014019:Tissue Donors; D014184:Transplantation, Homologous
D016827:CD8 Antigens; D015234:HLA-A Antigens; D010446:Peptide Fragments; D016044:Fusion Proteins, bcr-abl